Octreotide
| Octreotide | ||
|---|---|---|
|
||
| Structural formula | ||
| Mass / length primary structure | 8 amino acids, 1019 daltons | |
| Identifier | ||
| External IDs |
|
|
| Drug information | ||
| ATC code | H01 CB02 | |
| DrugBank | BTD00088 | |
Octreotide is a synthetic analogue of the peptide hormone somatostatin , which is used as a medicinal substance . Octreotide consists of eight amino acids ( D -Phe-cyclo [Cys-Phe- D- Trp-Lys-Thr-Cys] -Thr (ol)).
In Germany, octreotide u. a. approved for the treatment of acromegaly and certain gastrointestinal tumors ( GEP-NET , e.g. carcinoids ).
Coupled to 111 indium or 68 gallium ( edotreotide , DOTATOC) via DOTA , it is used in somatostatin receptor scintigraphy or in positron emission tomography (PET) to detect ( diagnose ) these tumors. For therapeutic purposes ( radionuclide therapy ) beta emitters such as 90 Yttrium or 177 Lutetium can be used.
Octreotide can be used to treat cluster headache attacks and secretory diarrhea when other drugs are ineffective or contraindicated.
Trade names
Bendatreotid (D), Sandostatin (D, A, CH), Octreo (A), Siroctid (A), as well as generics (D)
Web links
- European Medicines Agency: Summary of Product Characteristics Sandostatin
Individual evidence
- ↑ A. May et al. a .: EFNS guidelines on the treatment of cluster headache and other trigeminalautonomic cephalalgias. In: European Journal of Neurology. 13/2006, pp. 1066-1077. doi: 10.1111 / j.1468-1331.2006.01566.x , PMID 16987158 .
